{"brief_title": "Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)", "brief_summary": "The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) as a single agent in patients with Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia in Blast Crisis, or Acute Lymphoblastic Leukemia.", "condition": "Leukemia, Lymphocytic", "intervention_type": "Drug", "intervention_name": "Farnesyl Protein Transferase Inhibitor", "criteria": "Inclusion Criteria: - Pathologically documented chronic myelogenous leukemia in blast crisis, myelodysplasia, acute myelogenous leukemia, or acute lymphocytic leukemia. - Life expectancy of 12 weeks or greater. - ECOG Performance Status less than or equal to 2. - Meets protocol requirements for specified laboratory values. - No manifestations of a malabsorption syndrome. Exclusion Criteria: - Patients who have received more than three chemotherapy regimens for more than three recurrences of the disease. - Poor medical risks because of nonmalignant systemic disease as well as those with active uncontrolled conditions. - Patients who have received investigational therapy of any type within 30 days prior to administration.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00034684.xml"}